The potentially modifiable risk factor in idiopathic intracranial hypertension: body weight.
Mollan, Susan P Tahrani, Abd A Sinclair, Alexandra J
Mollan, Susan P
Tahrani, Abd A
Sinclair, Alexandra J
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2021-08
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Purpose of review: Idiopathic intracranial hypertension (IIH) prevalence increased in conjunction with rising obesity rates. Here, we highlight the importance of weight management in IIH and introduce glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) as potential treatment strategy for IIH.
Recent findings: Weight gain is a risk factor for IIH, and weight loss (via any treatment strategy) plays a key role in IIH management. GLP-1 is an incretin secreted by the distal small intestine in response to a meal. GLP-1 RAs have been shown to improve glycaemic control (no hypoglycaemia) and lower body weight in patients with and without type 2 diabetes. The choroid plexus has been found to express GLP-1 receptors, and treatment with a GLP-1 RA significantly reduces CSF secretion in vitro and intracranial pressure (ICP) in rodents.
Summary: New research evaluating the pathophysiology of IIH supports GLP-1 RA as a potential treatment for IIH via weight loss dependent and independent mechanism to directly reduce ICP.
Citation
Mollan SP, Tahrani AA, Sinclair AJ. The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension: Body Weight. Neurol Clin Pract. 2021 Aug;11(4):e504-e507. doi: 10.1212/CPJ.0000000000001063
Type
Article
Other
Other